Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Evaluate the Clinical Potential of 68GaNOTA-Anti-MMR-VHH2 for in Vivo Imaging of MMR-expressing Macrophages by Means of Positron Emission Tomography (PET) in Oncological Lesions,Cardiovascular Atherosclerosis,Syndrome With Abnormal Immune Activation and sarcoïdosis

NCT04758650 is registered in ClinicalTrials.gov with Universitair Ziekenhuis Brussel as lead sponsor.

NCT NCT04758650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04758650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Evaluate the Clinical Potential of 68GaNOTA-Anti-MMR-VHH2 for in Vivo Imaging of MMR-expressing Macrophages by Means of Positron Emission Tomography (PET) in Oncological Lesions,Cardiovascular Atherosclerosis,Syndrome With Abnormal Immune Activation and sarcoïdosis
Lead sponsor
Universitair Ziekenhuis Brussel
Phase
Phase 2
Overall status
Terminated
Start date
January 26, 2021
Completion date
January 8, 2025
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerosis of artery, cancer, cardiac sarcoidosis, carotid stenosis, hlh, hodgkin lymphoma, adult, non hodgkin lymphoma, sarcoidosis, solid malignancy located in the head and neck